Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.36 |
| ▸ | FAP | Q12884 | 11/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201571 | 0.94 | PDE5A (0.38) | DPP4FAPPDE4BPDE7ASSTR5 | |
| SCHEMBL8204820 | 0.92 | DPP4 (0.36) | DPP4FAPPDE4BPDE7ASSTR5 | |
| SCHEMBL16298496 | 0.92 | PDE4B (0.35) | DPP4FAPPDE4BPDE7ASSTR5 | |
| SCHEMBL6670564 | 0.92 | PDE4B (0.35) | DPP4FAPPDE4BPDE7ASSTR5 | |
| SCHEMBL10201548 | 0.88 | PDE4B (0.40) | DPP4FAPPDE4BPDE7APDE5A | |
| SCHEMBL16299629 | 0.86 | PDE5A (0.37) | DPP4FAPPDE4BPDE7ASSTR5 | |
| SCHEMBL16299631 | 0.85 | PDE5A (0.46) | DPP4FAPPDE4BPDE7APDE5A | |
| SCHEMBL10201520 | 0.85 | DPP4 (0.40) | DPP4FAPPDE4BPDE7APDE5A | |
| SCHEMBL8217539 | 0.84 | PDE5A (0.48) | PDE5A | |
| SCHEMBL10201510 | 0.84 | PDE5A (0.39) | DPP4FAPPDE4BPDE7APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160375028-A1 | ORGANIC COMPOUNDS | FIENBERG ALLEN A (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | DPP4 631/4885FAP 2208/4885PDE4B 8/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | DPP4 90/4885FAP 96/4885PDE4B 24/4885 |
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | DPP4 631/4885FAP 2208/4885PDE4B 8/4885 |
| US-20160375028-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | DPP4 631/4885FAP 2208/4885PDE4B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.